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Objectives. Endomyocardial biopsy samples from patients with 
idiopathic dilated cardiomyopathy were screened for the presence 
of enterovirus genome. Patients with enterovirus-positive samples 
were further studied with regard to disease course, histologic 
variables and response to interferon-alpha treatment. 
Background. Studies of patients with idiopathic dilated car- 
diomyopathy have reported widely divergent clinical outcomes, 
suggesting that there is no unique underlying pathogenetic mech- 
anism. 
Methods. Five left ventricular endomyocardial biopsy samples 
were screened for the presence of the enterovirus genome by an 
established in situ hybridization technique in combination with a 
histologic, histomorphometric and immunohistoiogic workup. The 
course of the disease was then prospectively followed for up to 50 
months. Virus-positive patients whose condition deteriorated were 
treated with interferon-alpha. 
Results. Of 77 patients, 20 (26%) had enterovirus-positive and 
57 (74%) enterovirus-negative biopsy samples. During a mean 
follow-up period of 25.8 -+ 13.7 months, 1 patient in the enterovirus- 
positive group and 11 in the enterovirus-negative group died. Four 
patients in the enterovirus-negative group underwent heart trans- 
plantation (p < 0.05). The surviving 19 enterovirus-positive 
patients had a decrease in mean left ventricular end-diastolic 
diameter from 66 to 61 mm (p < 0.05) and a mean increase in left 
ventricular ejection fraction from 0.35 to 0.43 (p < 0.05). In 
contrast, enterovirus-negative patients had no significant change 
in end-diastolic diameter or left ventricular ejection fraction. Four 
patients in the enterovirus-positive group whose condition deteri- 
orated were treated with a 6-month course of subcutaneous 
interferon-alpha (3 x 106 U every second day). This treatment 
induced hemodynamic improvement in all four patients and 
eliminated the persistent enteroviral infection in two. 
Conclusions. Enterovirus-positive patients have a better heart 
transplantation-free survival rate and hemodynamic course, with 
fewer histoiogic changes, than do enterovirus-negative patients. 
In addition, enterovirus-positive patients respond favorably to 
interferon-alpha treatment. These observations indicate that myo- 
cardial enteroviral infection with associated left ventricular dys- 
function is a distinct disease entity with a benign course. 
(J Am Coil Cardiol 1995;25:1170-5) 
Idiopathic dilated cardiomyopathy is diagnosed by the exclu- 
sion of any known disease that might induce heart muscle 
dysfunction (1). The hemodynamic course of idiopathic dilated 
cardiomyopathy is variable; spontaneous hemodynamic im- 
provement and stabilization can be expected in -34% to 39% 
of all patients (2,3). Therefore, it is assumed that the patho- 
genesis of the disease is not unique and represents he end 
stage of various cardiopathogenic factors, such as genetic 
disorders, nutritional defects, toxins, drugs and viral infections 
(4). Virus isolation in endomyocardial biopsy samples from 
patients with idiopathic dilated cardiomyopathy as been 
previously unsuccessful (5). However, recent developments in 
modern molecular biologic techniques, uch as in situ hybrid- 
ization and polymerase chain reaction, can detect enteroviral 
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genomes in patients with idiopathic dilated cardiomyopathy 
and myocarditis (6-14). Although in situ hybridization tech- 
niques have a very high sensitivity for enteroviral detection--as 
few as 20 viral copies are detectable (8)--sampling errors 
during endomyocardial biopsy may lead to underestimation of 
the percent of viral infection in patients with idiopathic dilated 
cardiomyopathy. In murine models of viral myocarditis, per- 
sistent infection of -0.01% of myocardial cells (15) could be 
shown, whereas the inflammatory reaction had largely sub- 
sided in the chronic stage of the disease (16). Thus, it is 
becoming evident hat a high proportion of human idiopathic 
dilated cardiomyopathy might develop from acute enteroviral 
myocarditis (17-19). 
Because the inflammatory reaction seems to be related 
more to active virus replication than to autoimmunity (15), 
immunosuppressive th rapy in idiopathic dilated cardiomyop- 
athy has become irrational; this is supported by the proved 
ineffectiveness of immunosuppressive therapy in placebo- 
controlled trials of myocarditis (20) and idiopathic dilated 
cardiomyopathy (21). However, coxsackievirus B3 replication 
can be inhibited by interferon in fetal human heart cells (22), 
human myocardial fibroblast cultures (23) and murine models 
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of encephalomyocarditis (EMC) virus and coxsackievirus B3 
myocarditis (24-26). The present study aimed to described the 
hemodynamic and clinical course of enterovirus-positive versus 
enterovirus-negative patients with idiopathic dilated cardio- 
myopathy. In addition, myocardial histomorphometric and 
immunohistologic variables, as related to the virus infection, 
were investigated as well as the effect of interferon-alpha 
therapy in those enterovirus-positive patients with hemody- 
namic deterioration. 
Methods 
Study protocol. Between July 1987 and May 1991, 80 
patients with left ventricular dysfunction of unknown origin 
according to World Health Organization/International Society 
and Federation of Cardiology (WHO/ISFC) definitions (1) 
were included in a longitudinal prospective trial. The observa- 
tion period was completed in September 1992. The investiga- 
tors had knowledge of the results of enterovirus detection. 
The following diagnostic procedures were performed on 
entry into the study: left heart catheterization; left ventricular 
endomyocardial biopsy; echocardiography; gated blood pool 
scanning; Swan-Ganz catheterization; standard laboratory 
tests; and a clinical and comprehensive anamnestic workup 
with determination of duration of preclinical symptoms, uch 
as the patient's ubjective impairment (e.g., dyspnea, angina 
pectoris, palpitations) or objective variables (e.g., first docu- 
mentation of a left bundle branch block, pathologic echocar- 
diographic findings). Because of the large number of entero- 
viruses (-70 distinct serotypes) that have been associated with 
human viral heart disease and the unspecificity of the results, 
serologic antibody studies for enteroviral detection were not 
performed. 
Follow-up examinations were performed in subsequent 12- 
to 18-month intervals and included Swan-Ganz catheterization 
at rest and during exercise, gated blood pool scanning, clinical 
and anamnestic workup, standard laboratory tests, echocardi- 
ography and electrocardiography. 
Techniques. Left heart catheterization (Judkins tech- 
nique), Swan-Ganz catheterization a d gated blood pool scan- 
ning were performed according to standard techniques (2). 
Cardiac biopsy. Biopsy samples were obtained from the 
posterolateral free wall of the left ventricle with a Cordis long 
sheet bioptome (5.4F, 7F). At least five biopsy samples were 
obtained and fixed by immersion (four samples with 4% 
buffered formalin, one sample in 1.5% glutaraldehyde and 
1.5% formaldehyde buffered with 0.2 mol phosphate buffer). 
The formalin-fixed biopsy samples were used for immunohis- 
tochemistry and in situ hybridization techniques as follows: 
Immunohistochemical analysis was performed on paraffin sec- 
tions to characterize inflammatory infiltrates. In each case, 
L-CA (CD 45; panleucocyte; Dakopatts, Copenhagen, Den- 
mark), KP 1 (CD 68; macrophages, monocytes, myeloid cells; 
Dakopatts), L 26 (B-cells, Dakopatts) and MT 1 (T cells; 
Biotest AG, Dreieich Germany) were used as primary antibod- 
ies. Binding was detected with the alcalic phosphatase- 
antialcalic phosphatase (APAAP) method. The number of 
positive cells/mm 2 of sectional area was determined. Morpho- 
metric investigations were performed on paraffin sections. 
Hematoxylin-eosin-stained s ctions were used for measure- 
ments of the fiber diameters. The diameters were measured on 
cross sections of myofibers in the nuclear egion. In the case of 
eccentric section profiles, the short diameter was chosen. Forty 
profiles/biopsy were evaluated. The volume fractions of inter- 
stitial space and collagen were determined according to stan- 
dard morphometric techniques with point counting on sections 
stained with Sirius red (special collagen stain). 
In addition, the sample fixed with glutaraldehyde and 
formaldehyde was embedded in plastic (Epon-Araldite), and 
0.5-/zm semithin sections were stained with alcaline toluidine 
blue and counterstained with paraphenylene diamine. The 
intracellular volume fraction of myofibrils was determined by 
point counting, as described elsewhere (2). The classification 
of myocarditis was performed on the basis of the "Dallas" 
criteria (27). 
In situ hybridization of the endomyocardial biopsy samples 
was performed according to techniques previously described in 
detail by Klingel et al. (15) and Kandolf et al. (28). Briefly, 
serial sections (4 /xm) were mounted on microscope slides, 
dewaxed from paraffin and hybridized with a sulfur-35-1abeled 
coxsackievirus B3 DNA probe (200 /xg/ml). The probe con- 
tained a virus-specific 6.2-kilobase (kb) and a 1.0-kb fragment 
corresponding to nucleotides 66 to 7128 of the full-length 
transcript of the coxsackievirus B3 viral genome. After hybrid- 
ization and autoradiography, at least 6 to 10 slides with three 
to four formaldehyde-fixed biopsy samples were evaluated for 
the presence of enteroviral genomes. 
Usually in patients everal cells were tested positive. In the 
case of a single-cell infection, only those patients were classi- 
fied as enterovirus positive, if this cell was positive in a 
consecutive tissue slice. 
Study patients. Patient selection. Eighty patients were pro- 
spectively included in this study between July 1987 and May 
1991. Each patient presented with either heart failure, arrhyth- 
mia or left bundle branch block of unknown origin. A precise 
workup of the patients could not identify an illness other than 
heart disease. Left heart catherization and coronary angiogra- 
phy demonstrated the presence of idiopathic dilated cardio- 
myopathy according to the definition of WHO/ISFC (1). 
Patients with coronary or valvular heart disease (except for 
mild mitral regurgitation), systemic hypertension, hypertrophic 
cardiomyopathy, predominant pericardial disease or systemic 
disease of the heart were not considered to have idiopathic 
dilated cardiomyopathy and were therefore excluded. For 
inclusion in the study, left ventricular ejection fraction <0.50 
was required. All 80 patients were white (mean age 48.2 years, 
range 19 to 67; 64 men [80%], 16 women [20%]). 
Patient classification. Patients were classified as having 
deteriorating idiopathic dilated cardiomyopathy if during the 
period between two examinations left ventricular ejection 
fraction decreased >0.05 or maximal mean pulmonary artery 
pressure increased >5 mm Hg, or both. Idiopathic dilated 
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Table 1. Clinical Characteristics of 77 Patients With Idiopathic 
Dilated Cardiomyopathy 
Enterovirus Enterovirus 
Positive Negative p 
(n : 20) (n = 57) Value 
Age (yr) 47.2 48.6 0.63 
% male 80 75.4 0.93 
% incidence of left bundle branch block 30 39 0.68 
Echo end-diastolic diameter (ram) 66 64 0.44 
Alcohol consumption (%) 
None 4(/ 31 
Rare 20 42 0.26 
<50 g/day 30 15 
>50 g/day 10 12 
Atrial fibrillation (%) 35 14 0.(14 
Treatment with ACEI (%) 80 81 0.74 
NYHA functional class (%) 
I 20 16 
II 45 47 0.41 
IIl 30 35 
IV 5 2 
Duration of preclinical symptoms (%) 
-<3 mo 33 29 
4-6 mo I4 14 0.9l 
>6 mo 53 57 
Mean (too) 25 25 
LVEF at rest 0.35 0.34 0.85 
Mean pulmonary artery pressure 
At rest (ram Hg) 2I 2l 0.96 
At maximal work load (mm Hg) 39 44 0.22 
Systolic arterial pressure (ram Hg) 131 130 0.57 
Heart rate at rest (beats/rain) 79 82 0.32 
Data presented are mean values. ACEI - angiotensin-converting enzyme 
inhibitor; Echo = echocardiographic; NYHA = New York Heart Association. 
cardiomyopathy s mptoms were considered lessened if left 
ventricular ejection fraction increased by >0.05 or maximal 
mean pulmonary artery, pressure decreased by 5 mm Hg, or 
both. Changes in left ventricular ejection fraction and pulmo- 
nary artery pressure within these limits were considered insig- 
nificant and did not result in a change in the patient's 
classification. 
Alcohol intake was graded on a scale of 0 to 3 (0 = no 
alcohol intake; 1 = alcohol on rare occasions; 2 = <50 g 
alcohol/day, 3 = ->50 g/day). No other drugs were consumed by 
any patient. 
Severity of heart failure was classified according to New 
York Heart Association functional class. 
Therapy. Patients were treated according to degree of 
heart failure with angiotensin-converting enzyme inhibitors, 
digitalis or diuretic agents. The treatment was comparable in 
both patient groups at the time of diagnosis (Table 1). Patients 
with previous tachycardiac syncope or resuscitation because 
of ventricular fibrillation received an automatic implantablc 
cardioverter-dcfibrillator. Dicumarole was given as an oral 
anticoagulant agent in patients with left ventricular ejection 
fraction <0.35 or atrial fibrillation. Four patients with entero- 
virus-positive biopsy samples and hemodynamic deterioration 
6 months after diagnosis received interferon-alphaza treatment 
(Roferon A, purchased by Roche, Basel, Switzerland) in 
evening subcutaneous dosages, 3.0 x 106 U every other day. 
The reinvestigation procedures and interferon treatment 
trial were approved by the University Hospital Committee of 
Ethics. Written informed consent was obtained from all pa- 
tients for all left heart catheterization a d biopsy procedures 
and interferon treatment. 
Statistics. Results are expressed as mean value _+ SD. Com- 
parisons between the enterovirus-positive and enterovirus- 
negative groups were made by the unpaired Student t test after 
consideration f equal group variances by means of the F test. 
A p value < 0.05 was considered significant. All tests per- 
formed were two sided. The hemodynamic course in different 
groups was dichotomized as improved or unchanged/ 
deteriorating and compared by the Fisher exact test. Other 
dichotomized variables were tested by the chi-square test. The 
variation of continuous variables within a group over time were 
tested by the paired Student t test. Survival rates were deter- 
mined by the Kaplan-Meier method. Heart transplantation 
and death were censored. For differences between groups the 
log-rank test was used. 
Resu l ts  
Hemodynamic course and survival. Light microscopic 
evaluation of left ventricular endomyocardial biopsy samples 
from the 80 study patients revealed 3(4%) with myocarditis (1 
virus positive, 2 negative, all improved) and 77 who were 
diagnosed as having idiopathic dilated cardiomyopathy. 
Twenty patients (26%) were shown to be enterovirus positive 
and 57 (74%) negative by means of in situ hybridization. 
Although the clinical characteristics at the time of diagnosis 
revealed no differences between the two groups with regard to 
duration of preclinical symptoms or history of acute infective 
illness (except for atrial fibrillation, which was more frequent 
in the enterovirus-positive group) (Table 1), the course of the 
disease differed in both groups. 
In the enterovirus-negative group, 11 patients (19%) died, 
and 4 (7%) underwent heart transplantation within a mean 
[_+SD] follow-up period of 24.3 + 13.0 months (6 patients died 
suddenly). In the enterovirus-positive group, one patient (5%) 
died of congestive heart failure within a mean follow-up period 
of 29.7 _+ 14.4 months. No heart ransplantation was necessary 
in this group. Thus, transplantation-free survival was signifi- 
cantly greater in the enterovirus-positive group (p < 0.05) (Fig. 
l). During a mean reevaluation period of 16.2 + 9.2 months in 
the enterovirus-negative group, hemodynamic function im- 
proved in only 10 patients (18%), was unchanged in 23 (40%) 
and deteriorated in 6 (11%); 3 patients did not appear for 
reevaluation but were still alive. During a mean reevaluation 
period of 19.2 + 8.9 months in the enterovirus-positive group, 
hemodynamic function improved in 11 patients (55%), re- 
mained unchanged in 3 (15%) and deteriorated in 4 (20%) 
(p < 0.02), who later underwent interferon treatment (Fig. 2); 
1 patient refused hemodynamic reevaluation but was still alive. 
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Figure 1. Heart ransplantation (HTX)-free survival without interferon- 
alpha treatment in enterovirus-positive and enterovirus-negative pa- 
tients with idiopathic dilated cardiomyopathy. Heart transplantation- 
free survival rate is higher in enterovirus-positive patients. 
Left ventricular ejection fraction at rest increased signifi- 
cantly from 0.35 _+ 0.13 to 0.43 _+ 0.09 in the virus-positive 
group (p < 0.05) (Fig. 3) but was unchanged in the virus- 
negative group (0.34 + 0.12 to 0.37 _+ 0.14, p = NS). Maximal 
pulmonary artery pressure remained unchanged in both the 
virus-positive (39 +_ 10 mm Hg [5.2 _+ 1.3 kPa] vs. 36 _+ 
12 mm Hg [4.8 _+ 1.6 kPa], p = NS) and virus-negative groups 
(44 _+ 13 mm Hg [5.9 _+ 1.7 kPa] vs. 45 _+ 15 mm Hg [6.0 + 
2.0 kPa], p = NS). However, according to echocardiographic 
end-diastolic diameter, virus-positive hearts became signifi- 
cantly smaller (from 66 to 61 mm, p < 0.05) than virus-negative 
hearts, which remained unchanged (64 vs. 65 mm, p = NS). 
Thus, according to the presence or absence of enterovirus 
within the myocardium, there was a striking difference in both 
hemodynamic course and major cardiac event rate (i.e., death 
or heart transplantation). 
Endomyoeardial biopsy. All endomyocardial biopsy sam- 
ples were subjected to histomorphometric evaluation, and 
immunohistochemistry was used in a subset of samples (n = 
30). The results of these tests are summarized in Table 2. The 
myofibril volume fraction (i.e., myofibril volume within a 
myocyte) was reduced in the enterovirus-negative group, but 
other histomorphometric features (myocyte diameter, intersti- 
tial volume fraction) did not differ. Immunohistologic studies 
revealed no striking differences; however, there was a trend to 
more macrophages and more panleukocytes, particularly T
lymphocytes in the enterovirus-positive biopsy samples (Table 2). 
Interferon-alpha treatment in a subset of enterovirus- 
positive patients. Endomyocardial biopsy samples from 20 
patients were enterovirus positive according to in situ hybrid- 
ization. Within 29.7 - 14.4 months, 1 patient died, 1 was lost 
to follow-up, and 14 were in hemodynamically or clinically 
stable or improved condition within 19.2 _+ 8.9 months. 
Therefore, none of these patients underwent interferon-alpha 
treatment, but four of them had hemodynamic deterioration i  
the mean 22.5 _+ 5.0 months after diagnosis. They were treated 
with 3.0 x 10 6 U of interferon-alpha (Roferon A) every other 
day subcutaneously for 6 months. Subsequent hemodynamic 
evaluation showed an increase in left ventricular ejection 
fraction in three patients; in one patient left ventricular 
ejection fraction was unchanged, but mean maximal pulmo- 
nary artery pressure was significantly reduced (from 43 to 
31 mm Hg) at comparable rgometric work loads. Clinical 
status also improved by one functional class in all patients. No 
adverse reactions, except for a slight fever at the start of the 
Figure 2. Flow diagram of the 80 study 
patients (pts) classified by in situ hybridiza- 
tion of left ventricular endomyocardial bi- 
opsy samples as having myocarditis or idio- 
pathic dilated cardiomyopathy (DCM). The 
57 enterovirus-negative (neg.) patients had 
a worse outcome during the mean observa- 
tion period of 29.7 months than the 20 
enterovirus-positive (pos.) patients. HTX = 
heart ransplantation. 
I 
80 pt s J 
DCM or Myocorditis I 
77 pts 
DCM 
/ 
> / M,°c° ° , i , /3  o,
pos, n:20 neg. n:57 
~ Inleffefon 
1174 FIGULLA ET AL. JACC Vol. 25, No. 5 
ENTEROVIRUS ASSOCIATED DILATED CARDIOMYOPATHY April 1995:1170-5 
LVEF / 
°i.i:Io  
0.20~ 
I I -J 
T O TI Tz 
• , Interferon 
Figure 3. Changes in left ventricular ejection fraction (LVEF) for each 
enterovirus-positive patient with idiopathic dilated cardiomyopathy. 
The four patients with hemodynamic deterioration received subse- 
quent treatment with interferon-alpha (3 × 106 U subcutaneously 
every other day) for 6 months. Left ventricular ejection fraction 
increased in three patients and was unchanged in one but improved 
by Swan-Ganz catheter measurements during treatment (T) with 
interferon-alpha. Solid lines with circles = those patients whose 
condition deteriorated and who received interferon-alpha. 
treatment, were observed. Changes in left ventricular ejection 
fraction for all enterovirus-positive patients is shown in Figure 
3 (n = 15). After completion of interferon treatment, subse- 
quent left ventricular endomyocardial biopsy revealed the 
persistence of the enterovirus genome in two patients, even 
though they both had improved hemodynamic function. 
Discussion 
Course of idiopathic dilated cardiomyopathy as related to 
myocardial enterovirus infection. To our knowledge, the 
present study included the largest group of patients with 
idiopathic dilated cardiomyopathy to be screened by in situ 
hybridization techniques for enterovirus-specific r bonucleic 
acid (RNA) in left ventricular myocardium. Enterovirus RNA 
was present in 26% of patients by in situ hybridization, which 
is capable of detecting as few as 20 virus copies (8) and is 
considered a powerful tool with high sensitivity and specificity 
for studying viral infection. However, differing results have 
been obtained with various molecular biologic techniques, 
ranging from 0% to 52% of RNA detection in various patient 
populations and biopsy sites (6-14). Because the technique 
used in the present study has a high specificity, it is unlikely 
that the percent of RNA detection was overestimated; rather, 
it was probably underestimated because of the sampling error 
inherent in the endomyocardial biopsy technique (29). 
Pathogenesis. The pathogenesis of virus-negative idio- 
pathic dilated cardiomyopathy is unknown. Structural disinteg- 
rity is more pronounced than in the enterovirus-positive dis- 
ease, as indicated by our measurements of the myofibril 
volume fraction in the endomyocardial biopsy samples (Table 
2). As shown in the present study, virus-negative idiopathic 
Table 2. Histomorphometric and Immunhistologic Endomyocardial 
Biopsy Results 
Enterovirus Enterovirus 
Postive Negative 
Mean Mean p 
No. _+SD No. _+SD Value 
Myofibrillar volume 18 57.5 + 4.3 53 55.1 ± 3.1 0.036 
fraction (%) 
Interstitial volume 15 25.5 + 11.6 45 24.8 + 8.1 0.82 
fraction (%) 
Myocyte diameter (/xm) 17 27.7 ± 5.6 51 29.1 ± 5.1 0.37 
Pan-bukocytes (1/mm z) 10 3.8 _* 3.5 20 2.4 ± 2.5 0.12 
Macrophages (1/mm z) 10 2.7 ± 3.9 20 1.0 ± 0.70 0.24 
T cells (l/mm 2) 10 5.1 -+ 5.3 20 3.4 ± 3.3 0.38 
B cells (l/ram z) 10 0.2 _+ 0.3 20 0.4 _+ 0.20 0.52 
dilated cardiomyopathy is correlated with deteriorating left 
ventricular function and, consequently, an adverse cardiac 
event rate. No clinical or hemodynamic feature indicated a 
higher prevalence for enteroviral heart disease, except for 
atrial fibrillation, which occurred more frequently in enterovirus- 
positive patients (Table 1). Thus, the present study did not 
permit investigation i to the mechanism that triggers or main- 
tains the persistent enterovirus infection or identification of 
features that are associated with a higher likelihood of entero- 
virus left ventricular dysfunction (other than atrial fibrillation). 
In a previous longitudinal study in 1985 (2), we found that 
"there are two groups of patients with idiopathic dilated 
cardiomyopathy that differ with respect o their hemodynamic 
course and morphologic features. This makes it more likely 
that the pathogenesis of the disease is not unique, and if it is 
not, the entity idiopathic dilated cardiomyopathy can be di- 
vided into a progressive and nonprogressive form." In the 
present study, we found that the virus-positive patients resem- 
bled those patients previously described with nonprogressive 
idiopathic dilated cardiomyopathy with a preserved myofibril 
volume fraction on endomyocardial biopsy. With the high 
prevalence of enterovirus infection in our subset of patients 
with idiopathic dilated cardiomyopathy, it is very likely that the 
morphologic and hemodynamic findings in the previous group 
were caused by the enterovirus infection and that myocardial 
enterovirus infection with left ventricular dysfunction is a 
distinct disease ntity. 
The partial reversibility or stabilization of the virus-induced 
left ventricular dysfunction might be explained by the sponta- 
neous or therapeutic (interferon-alpha) elimination of the 
virus and the concomitant inflammatory reaction. 
Interferon treatment in enterovirus-positive patients. Cox- 
sackie virus B3 replication can be inhibited in cell cultures and 
murine myocarditis experiments (22-26). To our knowledge, 
the present study is the first to investigate the effect of 
interferon-alpha treatment in a subset of patients with 
enterovirus-induced progressive left ventricular dysfunction. 
The dosage applied, 3.0 × 10 6 IU subcutaneously every other 
day for 6 months, was self-administered by the patients and 
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resembles concentrations that eliminated virus replication in 
human fibroblast cultures in a previous tudy of ours (30). The 
dosage is equivalent to that used in virus hepatitis B and C 
trials (31,32) and was well tolerated. There were only mild side 
effects: Three patients developed fever after the first injections, 
two complained of an influenza-like syndrome at the begin- 
ning, and one showed a transient elevation of transaminase 
levels. Although there are some case reports in which a higher 
dosage (-3 to 20 x 10 6 U/day) of interferon is suspected of 
causing reversible heart dilation (33,34) in patients without 
cardiac disease, on average in the present study, ejection 
fraction increased from 0.33 to 0.41, and mean pulmonary 
artery pressure at maximal work load decreased from 45 to 
33 mm Hg. After a 6-month treatment course, two of four 
patients were still enterovirus positive by in situ hybridization 
on subsequent biopsy, even though progressive l ft ventricular 
dysfunction was reversed. Whether this was due to a reduction 
rather than elimination of the virus or to a concomitant 
macrophage r action cannot be determined and warrants more 
investigation i larger groups of treated patients. However, the 
benign response to the interferon treatment in the present 
subset of patients further substantiates our concept hat left 
ventricular dysfunction is virus induced and can be partially 
reversed. 
Conclusions. The present results favor the view that 
enterovirus-associated left ventricular dysfunction is a distinct 
disease entity with a benign course undetectable byclinical, 
anamnestic or hemodynamic features from idiopathic dilated 
cardiomyopathy. Detection of enterovirus infection in a sub- 
group of idiopathic dilated eardiomyopathy patients further 
extends our understanding of the pathogenesis of this multi- 
factorial disease. 
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